Relay Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Relay Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials 4 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Relay Therapeutics: 5 sponsored US clinical trials, 4 recruiting.

Relay Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PIK3CA Mutation, with 4 trials.

Upper-quartile sponsor footprint

Relay Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

5 total, page 1 of 1

RECRUITING Phase 1

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

NCT07584226
RECRUITING Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521
RECRUITING Phase 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

NCT06789913
RECRUITING Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432
COMPLETED Phase 1

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

NCT05759949

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1
Phase 3 1

Therapeutic Areas

PIK3CA Mutation 4
Advanced Breast Cancer 3
HER2-Negative Breast Cancer 3
Breast Cancer 3
Metastatic Breast Cancer 3
Hormone Receptor Positive Tumor 2
Unresectable Solid Tumor 2
Solid Tumor, Adult 2
Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP) 1
Vascular Malformations 1

What is open in the Relay Therapeutics pipeline

4 recruiting of 5 indexed (80% open); 1 completed (20%).

Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: PIK3CA Mutation (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Relay Therapeutics: open-pipeline peers nationwide

Peers matched on 5 registered trials and 80% open enrollment, not the therapeutic-area sidebar.

Relay Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%20%40%60%80%100% Total trials Recruiting share Relay Therapeutics4YouandMeAbbott Rapid DxAccess Business GroupAcera SurgicalAlpha Tau MedicalBuck Institute for Research on AgingIDEAYA BiosciencesMapLight Therapeutics
Relay Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Relay Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 trials (± recruiting share)

Sponsors near 80% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Relay Therapeutics page

5 registered trials is a research-attention snapshot, not an endorsement of Relay Therapeutics or any single study.

  • 4 of Relay Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • PIK3CA Mutation is the condition Relay Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PIK3CA Mutation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Relay Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.